02-MicroRNA-381 Enhances Radiosensitivity in Esophageal Squamous Cell Carcinoma by Targeting X-Li

Text Material Preview

Full Terms & Conditions of access and use can be found at
https://www.tandfonline.com/action/journalInformation?journalCode=dott20
OncoTargets and Therapy
ISSN: (Print) (Online) Journal homepage: www.tandfonline.com/journals/dott20
MicroRNA-381 Enhances Radiosensitivity in
Esophageal Squamous Cell Carcinoma by
Targeting X-Linked Inhibitor of Apoptosis Protein
[Retraction]
To cite this article: (2023) MicroRNA-381 Enhances Radiosensitivity in Esophageal Squamous
Cell Carcinoma by Targeting X-Linked Inhibitor of Apoptosis Protein [Retraction], OncoTargets
and Therapy, , 311-312, DOI: 10.2147/OTT.S420793
To link to this article: https://doi.org/10.2147/OTT.S420793
© 2023 Dove Medical Press.
Published online: 11 May 2023.
Submit your article to this journal 
Article views: 142
View related articles 
View Crossmark data
https://www.tandfonline.com/action/journalInformation?journalCode=dott20
https://www.tandfonline.com/journals/dott20?src=pdf
https://www.tandfonline.com/action/showCitFormats?doi=10.2147/OTT.S420793
https://doi.org/10.2147/OTT.S420793
https://www.tandfonline.com/action/authorSubmission?journalCode=dott20&show=instructions&src=pdf
https://www.tandfonline.com/action/authorSubmission?journalCode=dott20&show=instructions&src=pdf
https://www.tandfonline.com/doi/mlt/10.2147/OTT.S420793?src=pdf
https://www.tandfonline.com/doi/mlt/10.2147/OTT.S420793?src=pdf
http://crossmark.crossref.org/dialog/?doi=10.2147/OTT.S420793&domain=pdf&date_stamp=11 May 2023
http://crossmark.crossref.org/dialog/?doi=10.2147/OTT.S420793&domain=pdf&date_stamp=11 May 2023
R E T R A C T I O N
MicroRNA-381 Enhances Radiosensitivity in Esophageal Squamous Cell 
Carcinoma by Targeting X-Linked Inhibitor of Apoptosis Protein 
[Retraction]
Zhou S, Cui Y, Yu D, Liang J, Zhang M, Ye W. Onco Targets Ther. 2017;10:2527–2538.
The Editor and Publisher of OncoTargets and Therapy are retracting the published article. Concerns were raised 
regarding the duplication of western blot images and an investigation found duplicated images in Figures 3 and 6. 
Specifically,
● The image in Figure 3D, TE10, c-caspase-3, has been duplicated with the same image from Figure 6C, TE10, 
c-PARP.
● The image in Figure 3D, TE10, c-PARP has been duplicated with the same image from Figure 3D, TE11, c-PARP.
● The image in Figure 3D, TE10/miR-381(+), c-caspase-3, has been duplicated with the same image from Figure 3D, 
TE11/miR-NC(-), Total PARP.
● The image in Figure 3D, TE11, Total PARP, has been duplicated with the same image from Figure 6C, TE11, Total 
caspase-3.
● The image from Figure 6C, TE10/shXIAP(+), c-PARP has been duplicated with the same image from Figure 6C, 
TE11/shcontrol(-), Total caspase-3.
The authors cooperated with the investigation but were unable to provide a satisfactory explanation regarding the 
duplicated images and were unable to verify the published work. Therefore, the Editor and Publisher are retracting the 
article and the authors have been notified.
We have been informed in our decision-making by our policy on publishing ethics and integrity and the COPE 
guidelines.
The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page 
as “Retracted”.
OncoTargets and Therapy Dovepress 
Publish your work in this journal 
OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential 
targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of 
management programs and new therapeutic agents and protocols on patient perspectives such as quality of life, adherence and satisfaction. The 
manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit 
http://www.dovepress.com/testimonials.php to read real quotes from published authors. 
Submit your manuscript here: https://www.dovepress.com/oncotargets-and-therapy-journal
OncoTargets and Therapy 2023:16 311 311
© 2023 Dove Medical Press. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/ 
terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing 
the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. 
For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
https://doi.org/10.2147/OTT.S420793
OncoTargets and Therapy Dovepress
open access to scientific and medical research
Open Access Full Text Article
Received: 10 May 2023
Accepted: 10 May 2023
Published: 11 May 2023
https://www.dovepress.com
http://www.dovepress.com/testimonials.php
http://www.dovepress.com/permissions.php
https://www.dovepress.com/terms.php
https://www.dovepress.com/terms.php
http://creativecommons.org/licenses/by-nc/3.0/
https://www.dovepress.com/terms.php
https://www.dovepress.com